Pharm'Up 
AstraZeneca has announced breakthrough results from its Phase III MIRANDA trial, demonstrating that its experimental biologic, tozorakimab, significantly reduces exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).
The study, which included over 1,400 participants, focused on individuals who continued to experience symptoms and flare-ups despite being on standard-of-care inhaled maintenance therapies. Tozorakimab works by targeting and neutralizing interleukin-33 (IL-33), a key protein responsible for triggering lung inflammation in response to triggers like infections and pollution.
Key Takeaways from the MIRANDA Trial:
- Reduced Flare-ups: Patients receiving the drug saw a statistically significant drop in moderate-to-severe exacerbations over a 52-week period.
- Broad Efficacy: Unlike many existing biologics that only work for specific “Type 2” inflammation profiles, tozorakimab showed benefits across a wide range of patients, including current and former smokers.
- Safety Profile: The drug was reported to be well-tolerated, with safety data consistent with previous smaller studies.
Professor Frank Sciurba, a lead investigator, noted that these findings are a “hopeful signal” for millions of patients who remain at risk of life-threatening respiratory events. AstraZeneca plans to submit the full data set to regulatory authorities soon, potentially positioning tozorakimab as a first-in-class treatment for a broad COPD population.
About the Author
